Technology

Platform

GliaX™

GliaPharm has established a proprietary drug discovery platform, GliaX™, centered on glial cells activity and brain metabolism.

Through this platform, the company is developing its pipeline program to establish a new class of agents for neuroprotection and maintenance of cognitive functions.

GliaX™ also serves collaboration with academic and industrial partners.

Brain metabolism
Morphology & activity
Cellular inflammation
Signalling cascades

Cell Types

Cerebral biosensors
EEG, FDG-PET, MRI
Preclinical disease models

Phenotype & Target based assays on Glial Cells

Primary brain cells Human iPSCs
Brain organoids
Neuron-Glia 
co-cultures

In vivo biomarkers Behavior

Brain metabolism
Morphology & activity Cellular inflammation Signalling cascades

Phenotype & Target based assays on Glial Cells

Cell Types

Primary brain cells Human iPSCs
Brain organoids
Neuron-Glia 
co-cultures

Cerebral biosensors
EEG, FDG-PET, MRI
Preclinical disease models

In vivo biomarkers Behavior

Harnessing the Power
of Glia

Phenotypic

assays

Brain metabolism
Cellular Viability
Cellular inflammation
Signalling cascades

Metabolic
assays

Brain cell cultures
Human iPSC model cultures
In vivo brain metabolite analysis

Target identification/

Chemistry

Al-driven target modelling
In vitro target identification
Small molecule design

Compound
characterisation
technologies

Brain organoids
Digital Holography Microscopy

Rodent
Behavioural
Tests

In-house behavioural capability in multiple rodent models

Translational
biomarkers

FDG PET/ MRI
EEG
Cerebrospinal Fluid (CSF)